Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population.

ABSTRACT:

Aims

This study is aimed at investigating the eligibility in a real-world heart failure population for the DAPA-HF (testing dapagliflozin) and EMPEROR-reduced (testing empagliflozin) trials, comparing the eligible real-world patients to trial participants and to characterize the noneligible patients.

Methods

Medical records of all heart failure patients who had a diagnosis of heart failure from the Heart Centre or Department of Internal Medicine at Umeå University Hospital were reviewed.

Results

2433 of the hospital's uptake population of 150 000 had a diagnosis of heart failure. 681 patients had left ventricle ejection fraction ≤ 40%, and of these 352 (52%) and 268 (39%) patients met eligibility criteria for DAPA-HF and EMPEROR-reduced, respectively. Comparing eligib

SUBMITTER: Hakansson E 

PROVIDER: S-EPMC8720587 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature